TBC1D22A is a protein encoded by the TBC1D22A gene in humans. Its name reflects its classification: TBC1 indicates that it contains a TBC (Tre-2, Bub2, and Cdc16) domain, which is typically associated with proteins that have GTPase-activating protein (GAP) activity towards small GTPases of the Rab family. The 'D22A' suffix denotes its specific gene identifier within this family.Proteins in this group, including TBC1D22A, are regulators of intracellular vesicle trafficking. They function by inactivating Rab GTPases, which play critical roles in directing vesicle transport along cytoskeletal tracks to different cellular compartments such as the Golgi apparatus, endosomes, lysosomes, and the plasma membrane. By acting as GAPs, TBC domain-containing proteins like TBC1D22A help control the timing of vesicle fusion and release, ensuring that cargo is delivered to the correct location within the cell.
The TBC1D22A protein may have specific substrates among the Rab GTPases, although the precise Rab targets and the pathways that TBC1D22A regulates are not well-characterized compared to other members of the TBC domain-containing protein family. It is likely involved in processes such as membrane trafficking, signal transduction, and cellular growth and differentiation.Mutations or dysregulation of proteins that control vesicle trafficking, like TBC1D22A, can lead to a wide array of cellular dysfunctions and are often implicated in diseases including neurological disorders, cancer, and metabolic syndromes.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts Golgi apparatus function and could indirectly affect TBC1D22A-related Rab GTPase activity. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
Nocodazole disrupts microtubule dynamics, affecting vesicular transport and potentially TBC1D22A function. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin, by elevating cAMP levels, can modulate various signaling pathways, possibly influencing TBC1D22A. | ||||||
9-[5-Deoxy-5-[[cis-3-[2-[6-(1,1-dimethylethyl)-1H-benzimidazol-2-yl]ethyl]cyclobutyl](1-methylethyl)amino]-β-D-ribofuranosyl]-9H-purin-6-amine | 1380288-87-8 | sc-500607 | 50 mg | $13500.00 | ||
ML141 is a Cdc42 inhibitor, potentially impacting pathways that intersect with TBC1D22A-related Rab GTPase activity. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $151.00 $609.00 | 75 | |
NSC23766 inhibits Rac1, which might have downstream effects on cellular processes involving TBC1D22A. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $165.00 $486.00 | 64 | |
Cytochalasin D disrupts actin filaments, affecting cell morphology and transport, potentially impacting TBC1D22A. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor, influencing vesicle trafficking and possibly TBC1D22A function. | ||||||
YM201636 | 371942-69-7 | sc-204193 | 5 mg | $217.00 | 6 | |
YM201636 inhibits PIKfyve, affecting endosomal trafficking, potentially relevant for TBC1D22A activities. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
Dynasore inhibits dynamin, affecting endocytosis and vesicular trafficking, potentially relevant for TBC1D22A. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine, affecting endosomal and lysosomal function, may have implications for TBC1D22A-related processes. | ||||||